Bio-Rad has sponsored the development of
this site to advance the productivity of the American Biotechnology sector and the fine people who
work in it across the country. We invite readers to contribute content:
posters, tools, research and presentations, articles white papers, multimedia, music
downloads and entertainment, conference announcements, videos. Please contact [email protected]for more information.
Download the Protein Blotting Guide
Download the Stem Cell Guide for Life Science Researchers
According to the YouTube description: When Carla Shatz, PhD, professor of neurobiology, and Helen Blau, PhD, professor of microbiology and immunology, came to Stanford in 1978, they were two of he first women to be hired on the tenure tract for basic science faculty. Over the decades, as their professional and personal paths have diverged and converged, they have remained the closest of friends. In this video, they discuss the courses their paths have taken and reflect on the rewards and challenges of their lives as women scientists.
Hat tip to the PostDoc Forum for pointing out this video.
Late last week, Geron Corporation announced that the FDA had given the company approval to move forward with the world’s first clinical trial of a human embryonic stem cell (hESC)-based therapy.The company is hoping that its GRNOPC1 therapy will restore spinal cord function to patients with subacute spinal cord injury by injecting hESC-derived oligodendrocyte progenitor cells directly into the lesion site of the patient’s injured spinal cord.
GRNOPC1, Geron’s lead hESC-based therapeutic candidate, contains hESC-derived oligodendrocyte progenitor cells that have demonstrated remyelinating and nerve growth stimulating properties leading to restoration of function in animal models of acute spinal cord injury (Journal of Neuroscience, Vol. 25, 2005).
The study had been placed in a hold pattern until recently since early results showed higher frequency of small cysts within the injury site in the spinal cord of animals injected with GRNOPC1. Further studies have demonstrated the safety of GRNOPC1 in laboratory animals prompting the FDA to grant a green light for the company to proceed with Phase 1 clinical trials.
According to Geron, in addition to spinal cord injury, GRNOPC1 may have therapeutic utility for other central nervous system indications such as Alzheimer’s Disease, Multiple Sclerosis and Canavan Disease.
The market acted quite favorably to the news with Aastrom Biosciences Inc. (NASDAQ:ASTM) and International Stem Cell Corporation (OTCBB:ISCO) stock jumping 10% and 6% respectively following Geron’s news release. A fairly comprehensive list of publicly traded stem cell companies can be found here.
Here’s he question of the day for those of you who are actively engaged in stem cell research at the bench: Has the news of the FDA’s approval of Geron’s clinical trial given you some extra motivation at the bench or are you unfazed by the glitz and glamor of the news media coverage of this event?
